The Rockefeller University » Anti–PD-1 in Cancer Therapy: Understanding Response and Resistance

Event Details

Type: Other Tri-Institutional Events
Speaker(s): Suzanne Topalian, M.D., professor of surgery and oncology, director, Melanoma Program, associate director, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
Open to: Public
Host: Dr. David Scheinberg
Contact: Jocette Marquez
Phone: (646) 888-3709
Sponsor: Jocette Marquez
(646) 888-3709
marquezj@mskcc.org

Related News

Some mammals can hit pause on a pregnancy. Understanding how that happens could help us treat cancer.

December 19, 2025

New study reveals the molecular brake that lets embryonic stem cells enter suspended animation, while retaining the ability to develop normally—which could shed light on abnormal cell growth in humans.

New engineered derivative of a natural molecule could translate into a powerful replacement for IVIG therapy for a wide array of autoimmune disorders

December 17, 2025

In experiments with mice, the new molecule accomplished the same job at a hundredth of the dose.

This new insight into T cell receptors may improve cancer immunotherapies

December 16, 2025

Researchers discovered that a crucial first step in the signaling system operates differently than previously thought, an insight that could lead to the next generation of treatments.